Tikun Olam-Cannbit Pharmaceuticals Ltd (TFSHF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tikun Olam-Cannbit Pharmaceuticals Ltd (TFSHF) trades at $1.50. Tikun Olam-Cannbit Pharmaceuticals Ltd. focuses on the research, development, cultivation, manufacture, and distribution of medical cannabis and related products. Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for TFSHF: TFSHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TFSHF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TFSHF: 1/1 perspectives are bearish.
How is this calculated? →Tikun Olam-Cannbit Pharmaceuticals Ltd (TFSHF) Healthcare & Pipeline Overview
Tikun Olam-Cannbit Pharmaceuticals Ltd. is an Israeli-based company specializing in the medical cannabis sector, focusing on research, development, cultivation, and distribution of cannabis products, along with patient care services. The company operates in a growing market with increasing acceptance of medical cannabis.
What Is the Investment Thesis for TFSHF?
Tikun Olam-Cannbit Pharmaceuticals Ltd. presents a focused investment opportunity within the burgeoning medical cannabis sector. The company's integrated business model, encompassing research, cultivation, manufacturing, and patient care, positions it to capture value across the cannabis value chain. Growth catalysts include increasing acceptance of medical cannabis globally and expansion into new therapeutic areas. However, potential risks include regulatory uncertainty, competition from larger pharmaceutical companies, and the inherent volatility of the cannabis market. Investors should closely monitor the company's financial performance, regulatory developments, and competitive landscape to assess the long-term viability of this investment.
Based on FMP financials and quantitative analysis
TFSHF Key Highlights
- Tikun Olam-Cannbit Pharmaceuticals Ltd. operates in the rapidly expanding medical cannabis market, projected to reach multi-billion dollar valuations in the coming years.
- The company's integrated business model allows for control over the entire value chain, from cultivation to patient care.
- Based in Israel, Tikun Olam-Cannbit benefits from a favorable regulatory environment for medical cannabis research and development.
- The company's focus on research and development positions it to innovate and create new medical cannabis products.
- Tikun Olam-Cannbit's patient care services provide a direct channel for product distribution and feedback.
Who Are TFSHF's Competitors?
TFSHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRON Cronos Group Inc. | $2.76 | -3.50% | $1.03B | 62 |
| CGC Canopy Growth Corporation | $0.96 | -4.00% | $405.27M | 46 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TFSHF's Key Strengths?
- Integrated business model.
- Strong brand reputation.
- Focus on research and development.
- Established relationships with healthcare providers.
What Are TFSHF's Weaknesses?
- Limited geographic reach.
- Dependence on regulatory approvals.
- Relatively small size compared to competitors.
- OTC listed
What Could Drive TFSHF Stock Higher?
- Potential regulatory changes in key markets could expand access to medical cannabis.
- Increasing acceptance of medical cannabis among healthcare professionals and patients.
- Expansion into new therapeutic areas through research and development.
- Strategic partnerships with other companies in the healthcare industry.
What Are the Key Risks for TFSHF?
- Regulatory uncertainty and changes in government policies.
- Competition from larger pharmaceutical companies.
- Negative public perception of cannabis.
- Price volatility in the cannabis market.
- Limited access to capital for smaller companies in the industry.
What Are the Growth Opportunities for TFSHF?
- Expansion into new therapeutic areas: Tikun Olam-Cannbit can leverage its research and development capabilities to explore the use of medical cannabis in treating a wider range of conditions, such as chronic pain, anxiety, and epilepsy. The global market for pain management is estimated to be worth billions of dollars, presenting a significant opportunity for the company. Timeline: Ongoing.
- Geographic expansion: As regulations surrounding medical cannabis evolve globally, Tikun Olam-Cannbit can expand its operations into new markets, such as Europe and North America. These regions represent significant growth opportunities due to their large populations and increasing acceptance of medical cannabis. Timeline: Ongoing.
- Development of new product formulations: Tikun Olam-Cannbit can invest in developing new and innovative product formulations, such as cannabis-infused edibles, topicals, and beverages. These products can appeal to a wider range of consumers and generate new revenue streams. The market for cannabis-infused products is growing rapidly, with significant potential for future expansion. Timeline: Ongoing.
- Strategic partnerships: Tikun Olam-Cannbit can form strategic partnerships with other companies in the healthcare and pharmaceutical industries to expand its reach and access new markets. These partnerships can provide access to new technologies, distribution channels, and customer bases. Timeline: Ongoing.
- Increased investment in research and development: By increasing its investment in research and development, Tikun Olam-Cannbit can develop new and innovative medical cannabis products that address unmet patient needs. This can lead to a competitive advantage and increased market share. The company's focus on research and development is crucial for long-term success in the rapidly evolving medical cannabis industry. Timeline: Ongoing.
What Opportunities Does TFSHF Have?
- Expansion into new markets.
- Development of new products.
- Strategic partnerships.
- Increasing acceptance of medical cannabis.
What Threats Does TFSHF Face?
- Regulatory changes.
- Competition from larger companies.
- Price volatility.
- Negative public perception of cannabis.
What Are TFSHF's Competitive Advantages?
- Proprietary cultivation and manufacturing processes.
- Strong brand reputation in the medical cannabis market.
- Established relationships with healthcare providers and patients.
- Focus on research and development of innovative medical cannabis products.
What Does TFSHF Do?
Tikun Olam-Cannbit Pharmaceuticals Ltd, based in Nof Hagalil, Israel, is a pharmaceutical company deeply rooted in the medical cannabis industry. The company engages in the research, development, cultivation, manufacture, and distribution of medical cannabis and related products. Beyond product development, Tikun Olam-Cannbit also provides essential training and patient care services, positioning itself as an integrated player in the medical cannabis ecosystem. Founded with the vision of providing high-quality medical cannabis solutions, Tikun Olam-Cannbit has evolved to meet the growing demands of patients and healthcare providers. The company's commitment to research and development allows it to continually innovate and refine its product offerings. Its cultivation and manufacturing processes adhere to strict quality standards, ensuring that patients receive safe and effective treatments. Tikun Olam-Cannbit's geographic focus is primarily within Israel, but the company may explore opportunities for expansion into other markets as regulations evolve and acceptance of medical cannabis increases globally. The company aims to be a leader in the medical cannabis industry through its commitment to science, quality, and patient care.
What Products and Services Does TFSHF Offer?
- Researches and develops medical cannabis products.
- Cultivates cannabis plants for medical use.
- Manufactures medical cannabis products.
- Distributes medical cannabis products to patients and healthcare providers.
- Provides training and education on the use of medical cannabis.
- Offers patient care services related to medical cannabis treatment.
How Does TFSHF Make Money?
- Generates revenue through the sale of medical cannabis products.
- Provides training and education services for healthcare professionals and patients.
- Offers patient care services, including consultations and treatment plans.
What Industry Does TFSHF Operate In?
The medical cannabis industry is experiencing significant growth, driven by increasing acceptance of cannabis for therapeutic purposes and evolving regulatory landscapes. Companies like Tikun Olam-Cannbit Pharmaceuticals Ltd. are positioned to capitalize on this trend by developing and distributing medical cannabis products. The industry is becoming increasingly competitive, with both established pharmaceutical companies and new entrants vying for market share. Success in this industry requires a strong focus on research and development, quality control, and regulatory compliance. The market is characterized by high growth potential but also significant regulatory and competitive challenges.
Who Are TFSHF's Key Customers?
- Patients seeking medical cannabis treatment.
- Healthcare providers prescribing medical cannabis.
- Pharmacies and dispensaries selling medical cannabis products.
Company Profile
Tikun Olam-Cannbit Pharmaceuticals Ltd operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Nof HaGalil, IL. The company is led by CEO Avinoam Sapir CPA. TFSHF has traded publicly since 2020.
ROE 127%Key Financial Metrics
Return on equity for Tikun Olam-Cannbit Pharmaceuticals Ltd stands at 126.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 10.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
TFSHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TFSHF Latest News
No recent news available for TFSHF.
TFSHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TFSHF.
Price Targets
Wall Street price target analysis for TFSHF.
TFSHF MoonshotScore
What does this score mean?
The MoonshotScore rates TFSHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Avinoam Sapir CPA
CEO
Avinoam Sapir is a Certified Public Accountant (CPA) and serves as the CEO of Tikun Olam-Cannbit Pharmaceuticals Ltd. His background in accounting and finance provides a strong foundation for managing the company's financial operations and strategic planning. With experience in the pharmaceutical industry, Avinoam brings a comprehensive understanding of the regulatory and market dynamics that shape the medical cannabis sector. His leadership is focused on driving growth, innovation, and operational excellence within the company.
Track Record: Since becoming CEO, Avinoam Sapir has overseen the company's efforts to expand its product portfolio and strengthen its market position. He has focused on building strategic partnerships and navigating the complex regulatory landscape of the medical cannabis industry. Under his leadership, Tikun Olam-Cannbit has continued to invest in research and development, positioning itself as a leader in the development of innovative medical cannabis products.
TFSHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Tikun Olam-Cannbit Pharmaceuticals Ltd. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Higher risk of fraud or manipulation.
- Lower liquidity and higher price volatility.
- Lack of regulatory oversight.
- Potential for delisting or suspension of trading.
- Verify the company's registration and licensing.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Research the company's products and services.
- Evaluate the company's competitive position.
- Understand the regulatory environment in which the company operates.
- Consult with a financial advisor.
- Company's history and track record in the medical cannabis industry.
- Positive media coverage and industry recognition.
- Partnerships with reputable healthcare providers.
- Commitment to research and development.
- Compliance with regulatory requirements.
What Investors Ask About Tikun Olam-Cannbit Pharmaceuticals Ltd (TFSHF) — Healthcare
What does Tikun Olam-Cannbit Pharmaceuticals Ltd do?
Tikun Olam-Cannbit Pharmaceuticals Ltd engages in the research, development, cultivation, manufacture, and distribution of medical cannabis and related products. The company operates primarily in Israel, providing medical cannabis products to patients and healthcare providers. Additionally, it offers training and patient care services, positioning itself as an integrated player in the medical cannabis value chain. The company's focus is on providing high-quality medical cannabis solutions for various therapeutic applications.
What are the main risks for TFSHF?
The main risks for Tikun Olam-Cannbit Pharmaceuticals Ltd include regulatory uncertainty, competition from larger pharmaceutical companies, and price volatility in the cannabis market. Regulatory changes could impact the company's ability to operate and sell its products. Competition from larger companies with greater resources could erode market share. Price volatility in the cannabis market could impact the company's revenue and profitability. Additionally, the company faces risks associated with operating in the OTC market, including limited liquidity and disclosure requirements.
What are the key growth opportunities for TFSHF in healthcare?
Key growth opportunities for Tikun Olam-Cannbit Pharmaceuticals Ltd lie in expanding its product offerings into new therapeutic areas, such as chronic pain, anxiety, and epilepsy. Geographic expansion into new markets, particularly in Europe and North America, also presents a significant growth opportunity. Furthermore, the development of new product formulations, such as cannabis-infused edibles and topicals, can attract a wider range of consumers. Strategic partnerships with other healthcare companies can also expand the company's reach and access to new markets.
What revenue streams does Tikun Olam-Cannbit Pharmaceuticals Ltd have in healthcare?
Tikun Olam-Cannbit Pharmaceuticals Ltd generates revenue primarily through the sale of medical cannabis products to patients and healthcare providers. Additional revenue streams include training and education services for healthcare professionals and patients, as well as patient care services. The company's revenue is dependent on the regulatory environment, market demand, and its ability to develop and distribute high-quality medical cannabis products. Revenue streams can be further diversified through expansion into new therapeutic areas and geographic markets.
What are the key factors to evaluate for TFSHF?
Evaluate TFSHF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does TFSHF data refresh on this page?
TFSHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TFSHF's recent stock price performance?
Tikun Olam-Cannbit Pharmaceuticals Ltd (TFSHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated business model. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TFSHF overvalued or undervalued right now?
Valuing Tikun Olam-Cannbit Pharmaceuticals Ltd (TFSHF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC stocks carry higher risk than exchange-listed stocks.